 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This is a signal that XENE's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Xenon Pharmaceuticals (XENE, $37.73) RSI Indicator left the overbought zone on December 04, 2023

VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the closing of its previously...

Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Collegium Pharmaceutical (NASDAQ:COLL  Get Free Report) and Xenon Pharmaceuticals (NASDAQ:XENE  Get Free Report) are both medical companies, but which is the better stock? We will...

Reviewing Xenon Pharmaceuticals (NASDAQ:XENE) and Collegium Pharmaceutical (NASDAQ:COLL)

VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on...

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)

This price move could be a signal that XENE may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Xenon Pharmaceuticals (XENE, $36.58) price may drop as it broke higher Bollinger Band on Nov 30, 2023

Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares are trading higher by 7.8% to $36.38 Thursday afternoon. The company announced the pricing of its upsized $300 million public offering of 8,461,542...

Why Xenon Pharmaceuticals Stock (XENE) Is Seeing Blue Skies Today

VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) ( Xenon ), a neurology-focused biopharmaceutical company, today announced the pricing of its...

Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Xenon Pharmaceuticals announces $225M common share offering

VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) ( Xenon ), a neurology-focused biopharmaceutical company, today announced that it has...

Xenon Pharmaceuticals Announces Proposed Public Offering

Xenon Pharmaceuticals (NASDAQ:XENE  Free Report) had its price target raised by Royal Bank of Canada from $51.00 to $56.00 in a research report report published on Tuesday, Benzinga reports...

Xenon Pharmaceuticals (NASDAQ:XENE) Given New $56.00 Price Target at Royal Bank of Canada

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Watchers	2,588
52-Wk Low	$27.99
52-Wk High	$43.75

Market Cap	$2.79B
Volume (M)	506,754.00
52-Wk High	$43.75
52-Wk Low	$27.99

XENE Xenon Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals